Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape.

[1]  Hua Yu,et al.  TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. , 2013, Blood.

[2]  X. Chen,et al.  Argonaute 2 Complexes Selectively Protect the Circulating MicroRNAs in Cell-Secreted Microvesicles , 2012, PloS one.

[3]  Juliane Nguyen,et al.  Nucleic acid delivery: the missing pieces of the puzzle? , 2012, Accounts of chemical research.

[4]  R. Figlin,et al.  S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. , 2012, Cancer cell.

[5]  H. Ploegh,et al.  Granulin is a soluble cofactor for toll-like receptor 9 signaling. , 2011, Immunity.

[6]  D. Zamboni,et al.  A Method for Generation of Bone Marrow-Derived Macrophages from Cryopreserved Mouse Bone Marrow Cells , 2010, PloS one.

[7]  Hua Yu,et al.  Stat3-induced S1PR1 expression is critical for persistent Stat3 activation in tumors , 2010, Nature Medicine.

[8]  O. Voinnet,et al.  Control of RNA silencing and localization by endolysosomes. , 2010, Trends in cell biology.

[9]  C. Kurts,et al.  Cross-priming in health and disease , 2010, Nature Reviews Immunology.

[10]  E. Gilboa,et al.  Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay , 2010, Nature.

[11]  D. Dykxhoorn,et al.  Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.

[12]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[13]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[14]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[15]  B. Freedman,et al.  Mechanism and Regulatory Function of CpG Signaling via Scavenger Receptor B1 in Primary B Cells* , 2009, The Journal of Biological Chemistry.

[16]  John J. Rossi,et al.  The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.

[17]  N. Escriou,et al.  Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. , 2008, Blood.

[18]  Svetlana Shulga Morskaya,et al.  5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma , 2008, Nature Medicine.

[19]  Sarah E. Ewald,et al.  The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor , 2008, Nature.

[20]  B. Pulendran,et al.  Cross-presentation: avoiding trafficking chaos? , 2008, Nature Immunology.

[21]  A. Judge,et al.  2'-O-methyl-modified RNAs act as TLR7 antagonists. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  A. Pasquinelli,et al.  MicroRNA silencing through RISC recruitment of eIF6 , 2007, Nature.

[23]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[24]  R. Medzhitov,et al.  On regulation of phagosome maturation and antigen presentation , 2006, Nature Immunology.

[25]  D. Klinman,et al.  CXCL16 Influences the Nature and Specificity of CpG-Induced Immune Activation12 , 2006, The Journal of Immunology.

[26]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[27]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[28]  G. Rettig,et al.  Progress Toward In Vivo Use of siRNAs-II , 2006, Molecular Therapy.

[29]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[30]  N. Zhong,et al.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.

[31]  R. Shiekhattar,et al.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing , 2005, Nature.

[32]  Mark E. Davis,et al.  Functional polarity is introduced by Dicer processing of short substrate RNAs , 2005, Nucleic acids research.

[33]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[34]  Sangdun Choi,et al.  Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy , 2005, Nature Biotechnology.

[35]  M. Welte,et al.  Bidirectional Transport along Microtubules , 2004, Current Biology.

[36]  B. Monks,et al.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome , 2004, Nature Immunology.

[37]  S. Akira,et al.  A Subset of Toll-Like Receptor Ligands Induces Cross-presentation by Bone Marrow-Derived Dendritic Cells1 , 2003, The Journal of Immunology.

[38]  B. Samuelsson,et al.  Ribonuclease activity and RNA binding of recombinant human Dicer , 2002, The EMBO journal.

[39]  Sergio Grinstein,et al.  Phagosome maturation: aging gracefully. , 2002, The Biochemical journal.

[40]  Etienne Gagnon,et al.  Endoplasmic Reticulum-Mediated Phagocytosis Is a Mechanism of Entry into Macrophages , 2002, Cell.

[41]  W. Filipowicz,et al.  Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Freeman,et al.  The collagenous domains of macrophage scavenger receptors and complement component C1q mediate their similar, but not identical, binding specificities for polyanionic ligands. , 1993, The Journal of biological chemistry.

[43]  F. Maxfield,et al.  Endocytic recycling , 2004, Nature Reviews Molecular Cell Biology.